Decrease in LFC for all doses (23, 19, 21% vs. 2% increase for placebo)Trend to improvement of fibrosis by NIT’s (PIIINP and NAFLD Fibrosis Score)Improvement in HbA1c and insulin sensitivity. No effect on body weight. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.